Delving into the Latest Updates on Beijing Institute of Radiation Medicine with Synapse

Overview

Tags

Respiratory Diseases

Nervous System Diseases

Neoplasms

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
Chemical drugs	1

Top 5 Target	Count

TLR1 x TLR2	1
PRKDC(DNA-dependent protein kinase)	1

Radiation dose assessment is the main basis for the diagnosis of acute radiation sickness. At present, there is a lack of rapid and portable dose assessment methods, which has an important impact on the rapid diagnosis and precise treatment of radiation accident patients and nuclear practitioners. We selected and obtained specific aptamers for radiation-sensitive protein p21 protein by the magnetic cross-linking precipitation (MCP)-SELEX procedure. The aptamer has a high affinity for binding to the p21 protein and its K_d value is 2.21 × 10^-7 mol/L. We subsequently established a new method for radiation dose assessment of an electrochemical impedance (EIS) aptasensor with screen-printed electrode chips. There was a good dose-effect relationship between the p21 protein expression level in PBMCs in human peripheral blood detected by this method within the dose range of 0-10 Gy, and detection limit of radiation dose is 0.38 Gy (LOD, S/N = 3). This dose range covers the diagnostic range of acute radiation sickness in the bone marrow. This method is not only portable but also fast, saving hours to days compared with the previous dose assessment method based on radiation sensitive protein. It can be applied to the rapid and portable diagnosis of acute radiation sickness.

01 Jul 2025·Cancer Letters

HNF4A functions as a hepatocellular carcinoma oncogene or tumor suppressor depending upon the AMPK pathway activity status

Article

Author: Ding, Chen ; Li, Yan ; Wang, Bing ; Bai, Yihe ; Li, Kai ; He, Fuchu ; Shi, Wenhao ; Yang, Wenjun ; Zhuang, Aojia ; Song, Lei ; Shao, Xiexiang ; Ma, Fahan ; Qin, Zhaoyu

Cancer cells frequently undergo energy metabolic stress induced by the increased dynamics of nutrient supply. Hepatocyte nuclear factor 4A (HNF4A) is a master transcription factor (TF) in hepatocytes that regulates metabolism and differentiation. However, the mechanism underlying how HNF4A functions in cancer progression remains unclear due to conflicting results observed in numerous studies. To address the roles of HNF4A in hepatocellular carcinoma (HCC), we investigated the regulatory functions of HNF4A in HCC cells under different glucose supply conditions. We found that HNF4A exhibited tumor-suppressive effects on the proliferation and migration of HCC cells in glucose-sufficient conditions and tumor-promotive effects on HCC cells in glucose-insufficient conditions. Further investigation revealed that this diverse function of HNF4A was dependent upon the AMPK pathway activity. Similarly, the prognosis predicted by HNF4A was also correlated with whether the AMPKa expression levels were low or high in clinical HCC patients. Multiomics approaches consisting of proteomics and ChIP-seq revealed that key HNF4A target genes, including NEDD4 and RPS6KA2, are involved in the diverse function of HNF4A in HCC in response to the AMPK activity status. Specifically, HNF4A could bind to the promoter region of NEDD4 and RPS6KA2, and upregulating their expression. Our study has demonstrated the relationship between and synergism of AMPK and HNF4A in the progression of HCC under diverse nutrient conditions.

01 Jun 2025·European Journal of Medicinal Chemistry

Discovery of a novel quinoxaline derivative modulator via a dual P53/TLR2 targeting strategy for the alleviation of radiation damage

Article

Author: Cui, Yaowen ; Chen, Tingting ; Peng, Tao ; Song, Li ; Wang, Lin ; He, Zhaolun ; Zhang, Shouguo ; Yang, Xin ; Liu, Shuchen ; Xu, Jing

With the development of nuclear technology, the risk of people being exposed to nuclear radiation is increasing. So the development of efficient and safe radiation protection agents for nuclear emergencies is urgent. In this study, a series of novel quinoxaline molecules were designed and synthesized with Ex-RAD and TLR2 agonist as the lead, showing anti-radiation effects and compound Z9 was the best one of them. Our work indicated that Z9 emerged as a potent dual modulator targeting both TLR2 and P53 pathway, remarkably preventing the radiation-induced death in mice with the survival rate of 100 %. In the same time, Z9 had significant radioprotection of the haematopoietic system and intestinal villi in mice. In addition, Z9 significantly reduced radiation-induced apoptosis, DNA damage, P53 and Bax expression of AHH-1, while Z9 up-regulated the expressions of TLR2 downstream proteins MyD88 and P65 of HUVECs. Notably, Z9 showed excellent stability and affinity for the TLR2 protein conjugate in molecular docking and molecular dynamics simulations. These findings suggested that Z9 was worth further research being a potential candidate for anti-radiation drugs, as the dual modulator of P53/TLR2.

100 Deals associated with Beijing Institute of Radiation Medicine

Login to view more data

100 Translational Medicine associated with Beijing Institute of Radiation Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Quercetin nanoparticles	Dyssomnias More	Preclinical
VND3207 ( PRKDC )	Fibrosis of lung caused by radiation More	Preclinical
WYJ-2 ( TLR1 x TLR2 )	Non-Small Cell Lung Cancer More	Discovery
AXL-CAR-T cells (Beijing Institute of Radiation Medicine) ( AXL )	Triple Negative Breast Cancer More	Pending
pUDK-HGF(Beijing Institute of Radiation Medicine) ( HGF )	-	Pending